Back

Phase Ib study of intravenous HRS-9057, an arginine vasopressin V2 receptor antagonist, versus oral tolvaptan in congestive heart failure with volume overload despite prior diuretic therapy

31 August 2026 (12:00 - 12:10)
Organised by: Logo
Congress Presentation Part of: Transforming heart failure with next-generation therapies and mechanisms Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Wenchao Ou

(China)

4 More presentations in this session

Presentation thumbnail
Comparative effectiveness of finerenone versus spironolactone in patients hospitalized with heart failure: a prospective cohort study
Doctor R. Xiao (Chongqing, CN)
Abstract
Presentation thumbnail
Optimizing mineralocorticoid receptor antagonist therapy with sodium zirconium cyclosilicate in heart failure
Doctor C. Basic (Gothenburg, SE)
Abstract
Presentation thumbnail
The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT study
Doctor F. Cappelli (Florence, IT)
Abstract
Presentation thumbnail
Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart
Doctor Y. Wang (CN)
Abstract

Access the full session

Session thumbnail
Transforming heart failure with next-generation therapies and mechanisms

The Event

Event poster

ESC Congress 2026

31 August 2026 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of early initiation of low-dose tolvaptan in elderly patients more than 90 years old with acute congestive heart failure
21 May 2023
thumbnail
Congress Presentation
Peripheral venous pressure guided decongestive therapy in heart failure (PERIPHERAL-HF)
20 May 2023
thumbnail
Congress Presentation
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
31 August 2019
thumbnail
Congress Presentation
Altered arginin-vasopressin (AVP)/apelin system balance in congestive heart failure patients under diuretic resistance: results from a pilot study
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources